Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: A pilot study

Medical Science Monitor

Volumn 15, Issue 12, 2009, Pages

  Bilinska, Maria ^a   Wolszakiewicz, Jadwiga ^a   Duda, Monika ^b   Janas, Jadwiga ^a   Beresewicz, Andrzej ^b   Piotrowicz, Ryszard ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Coronary artery disease; Inflammation; Isoprostanes; Oxidative stress; Sulodexide

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HEPARIN; ISOPROSTANE; SULODEXIDE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG SAFETY; HUMAN; INFLAMMATION; LEUKOCYTE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIOXIDANTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DINOPROST; FIBRINOGEN; GLYCOSAMINOGLYCANS; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LIPIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS;

EID: 75149154826     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lauver AD, Lucchesi BR: Sulodexide: A renewed interest in this glycosaminoglycan. Cardiovascular Drug Reviews, 2006; 24: 214-26
2. Callas DD, Hoppensteadt DA, Jeske W et al: Comparative pharmacologic profile of a glycosaminogycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide. Semin Thromb Hemost, 1993; 19(Suppl.1): 49-57
3. Errichi BM, Cesarone MR, Belcaro G et al: Prevention of recurrent deep venous thrombosis with sulodexide: The San Val registry. Angiology, 2004; 55: 243-49
4. Coccheri S, Scondotto G, Agnelli G et al: Randomized, double-blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost, 2002; 87: 947-52
5. Coccheri S, Scondotto G, Agnelli G et al: Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J, 2002; 23: 1057-65
6. Gambaro G, Cavazzana AO, Luzi P et al: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int, 1992; 42: 285-91
7. Achour A, Kacem M, Dibej K et al: One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol, 2005; 18: 568-74
8. Gambaro G, Kinalska I, Oksa A et al: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. Am Soc Nephrol, 2002; 13: 1615-25
9. Radhakrishnamurthy B, Sharma C, Bhandaru RR et al: Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis, 1986; 60: 141-49
10. Deepa PR, Varalakshmi P: Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chem Biol Interact, 2003; 146: 201-10
11. Ross MA, Long WF, Williamson FB: Inhibition by heparin of Fe(II)-catalysed free-radical peroxidation of linolenic acid. Biochem J, 1992; 286: 717-20
12. Albertini R, Passi A, Abuja PM, De Luca G: The effect of glycosaminoglycans and proteoglycans on lipid peroxidation. Int J Mol Med, 2000; 6: 129-36
13. Karlsson K, Marklund SL: Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J, 1987; 242: 55-59
14. Jung O, Marklund SL, Geiger H et al: Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res 2003;93: 622-9.
15. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-44
16. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation, 2003; 108: 1912-16
17. Le Brocq M, Leslie SJ, Milliken P, Megson IL: Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal, 2008; 10: 1631-74
18. Kiliszek M, Maczewski M, Styczynski G et al: LDL reduction by simvastatin is accompanied by AT1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease. Coron Artery Dis, 2007; 18: 201-9
19. Morrow JD, Hill KE, Burk RF et al: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA, 1990; 87: 9383-87
20. Lawson JA, Rokach J, FitzGerald GA: Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem, 1999; 274: 24441-4
21. Guzik TJ, West NE, Black E et al: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res, 2000; 86: E85-E90
22. Nickenig G, Sachinidis A, Michaelsen F et al: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation, 1997; 95: 473-78
23. Rajagopalan S, Kurz S, Munzel T et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide-production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest, 1996; 97: 1916-23
24. Wassmann S, Laufs U, Baumer AT et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001; 37: 1450-57
25. Wagner AH, Kohler T, Ruckschloss U et al: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 2000; 20: 61-69
26. Lauver DA, Booth EA, White AJ et al: Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther, 2005; 312: 794-800
27. Harenberg J: Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev, 1998; 18: 1-20
28. Diaz MN, Frei B, Vita JA, Keaney JF Jr: Antioxidants and atherosclerotic heart disease. N Engl J Med, 1997; 337: 408-16
29. Wienbrenner T, Cladellas M, Covas MI et al: High oxidative stress in patients with stable coronary artery disease. Atherosclerosis, 2003; 168: 99-106
30. Williams ME, Tuttle KR: The next generation of diabetic nephropathy therapies: an update. Adv Chronic Kidney Dis, 2005; 12: 212-22
31. Williams ME: New potential agents in treating diabetic kidney disease: the fourth act. Drugs, 2006; 66: 2287-98
32. Roberts LJ, Morrow JD: Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 2000; 28: 505-13
33. Schwedhelm E, Bartling A, Lenzen H et al: Urinary 8-iso-prostaglandin F2a as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation, 2004; 109: 843-48
34. Keaney JF Jr, Larson MG, Vasan RS et al: Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol, 2003; 23: 434-39
35. Devaraj S, Hirany SV, Burk RF, Jialal I: Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem, 2001; 47: 1974-79